Edap Tms SA
NASDAQ:EDAP

Watchlist Manager
Edap Tms SA Logo
Edap Tms SA
NASDAQ:EDAP
Watchlist
Price: 2.47 USD -0.8% Market Closed
Market Cap: 91.6m USD
Have any thoughts about
Edap Tms SA?
Write Note

Edap Tms SA
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Edap Tms SA
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Edap Tms SA
NASDAQ:EDAP
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biomerieux SA
PAR:BIM
PP&E Gross
€1.6B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Carmat SA
PAR:ALCAR
PP&E Gross
€10.1m
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
30%
Biosynex SA
PAR:ALBIO
PP&E Gross
€15.7m
CAGR 3-Years
45%
CAGR 5-Years
81%
CAGR 10-Years
44%
Visiomed Group SA
PAR:ALVMG
PP&E Gross
€5.2m
CAGR 3-Years
158%
CAGR 5-Years
37%
CAGR 10-Years
26%
Amplitude Surgical SA
PAR:AMPLI
PP&E Gross
€41.5m
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
No Stocks Found

Edap Tms SA
Glance View

Market Cap
91.2m USD
Industry
Health Care

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 227 full-time employees. The firm operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The firm invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The firm is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The firm is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.

EDAP Intrinsic Value
7.06 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

Back to Top